0001739174 false 0001739174 2022-03-30 2022-03-30 0001739174 PHGE:UnitsEachConsistingOfOneShareOfCommonStock0.0001ParValueAndOneWarrantEntitlingHolderToReceiveOneHalfShareOfCommonStockMember 2022-03-30 2022-03-30 0001739174 PHGE:SharesOfCommonStock0.0001ParValueMember 2022-03-30 2022-03-30 0001739174 PHGE:WarrantsEachExercisableForOnehalfOfShareOfCommonStock0.0001ParValueAtExercisePriceOf11.50PerShareMember 2022-03-30 2022-03-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares





Washington, D.C. 20549


Form 8-K



Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): March 30, 2022


  BiomX Inc.  
  (Exact Name of Registrant as Specified in its Charter)  


Delaware   001-38762   82-3364020
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)


22 Einstein St., Floor 5

Ness Ziona, Israel

(Address of Principal Executive Offices)   (Zip Code)


Registrant’s telephone number, including area code: +972 723942377


  (Former name or former address, if changed since last report)  


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on
which registered
Units, each consisting of one share of Common Stock, $0.0001 par value, and one Warrant entitling the holder to receive one half share of Common Stock   PHGE.U   NYSE American
Shares of Common Stock, $0.0001 par value   PHGE   NYSE American
Warrants, each exercisable for one-half of a share of common stock, $0.0001 par value, at an exercise price of $11.50 per share   PHGE.WS   NYSE American


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 2.02 Results of Operations and Financial Condition.


On March 30, 2022, BiomX Inc., or the Company, issued a press release announcing its financial results for the fourth quarter ended December 31, 2021. A copy of the press release issued in connection with the announcement is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.


Item 7.01 Regulation FD Disclosure.


The Company from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. On March 30, 2022, the Company posted an updated corporate slide presentation in the “Investors” portion of its website at www.biomx.com. A copy of the slide presentation is furnished pursuant to Item 7.01 as Exhibit 99.2 hereto. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits


Exhibit   Description
99.1   Press Release dated March 30, 2022
99.2   Investor Presentation dated March 30, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL documents)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


March 30, 2022 By: /s/ Jonathan Solomon
    Name:   Jonathan Solomon
    Title:  Chief Executive Officer